ADVANCED PHARMACOLOGY -
NSG6005 FINAL EXAM
COMPREHENSIVE STUDY GUIDE
SOUTH UNIVERSITY (CORRECT Q & A)
SATISFACTION GUARANTEED
1. A patient with chronic kidney disease (CKD) is prescribed Metformin for Type 2 Diabetes.
What is the primary reason this medication is often contraindicated when the Glomerular
Filtration Rate (GFR) falls below 30 mL/min/1.73m2?
A. Risk of severe hypoglycemia due to impaired renal excretion
B. Reduced effectiveness of the drug in acidic environments
C. Accumulation of the drug leading to lactic acidosis
D. Increased risk of secondary hyperparathyroidism
Answer: C
Conceptual Explanation: Metformin is primarily excreted unchanged by the kidneys. In
severe renal impairment, it can accumulate, significantly increasing the risk of lactic
acidosis, a rare but life-threatening metabolic complication.
2. When prescribing a Cytochrome P450 3A4 (CYP3A4) inducer like Rifampin to a patient
taking Warfarin, what clinical adjustment should the practitioner anticipate?
A. Decrease the Warfarin dose to prevent toxicity
,B. Discontinue Warfarin and switch to a Direct Oral Anticoagulant (DOAC)
C. Increase the Warfarin dose to maintain therapeutic INR
D. No adjustment is needed as Rifampin affects the 2C9 isoenzyme only
Answer: C
Conceptual Explanation: Rifampin is a potent inducer of hepatic enzymes, including those
that metabolize Warfarin. Induction leads to faster metabolism and decreased serum levels
of Warfarin, necessitating a higher dose to maintain the therapeutic International
Normalized Ratio (INR).
3. A patient is diagnosed with Heart Failure with Reduced Ejection Fraction (HFrEF). Which
medication class has been shown to reduce both morbidity and mortality by inhibiting the
effects of the sympathetic nervous system on the myocardium?
A. Loop Diuretics
B. Beta-Adrenergic Blockers
C. Calcium Channel Blockers
D. Cardiac Glycosides
Answer: B
Conceptual Explanation: Beta-blockers (specifically Carvedilol, Metoprolol Succinate, and
Bisoprolol) are essential in HFrEF management because they counteract the deleterious
, effects of chronic sympathetic nervous system activation, improving survival and cardiac
function.
4. In the context of pharmacokinetics, what does the term ‘Volume of Distribution’ (Vd)
primarily represent?
A. The total volume of blood in the human body
B. The theoretical volume required to contain the total amount of drug at the same
concentration as in the plasma
C. The rate at which a drug is cleared from the systemic circulation by the liver
D. The ratio of the dose administered to the total body weight
Answer: B
Conceptual Explanation: Vd is a theoretical value that relates the amount of drug in the
body to the concentration measured in the plasma. A high Vd suggests the drug is
extensively distributed into tissues, while a low Vd suggests it remains mostly in the
vascular space.
5. Which of the following describes the mechanism of action of Angiotensin II Receptor
Blockers (ARBs) that distinguishes them from ACE Inhibitors?
A. They block the conversion of Angiotensin I to Angiotensin II
B. They directly inhibit the release of Renin from the juxtaglomerular cells
C. They increase the levels of Bradykinin, leading to vasodilation
NSG6005 FINAL EXAM
COMPREHENSIVE STUDY GUIDE
SOUTH UNIVERSITY (CORRECT Q & A)
SATISFACTION GUARANTEED
1. A patient with chronic kidney disease (CKD) is prescribed Metformin for Type 2 Diabetes.
What is the primary reason this medication is often contraindicated when the Glomerular
Filtration Rate (GFR) falls below 30 mL/min/1.73m2?
A. Risk of severe hypoglycemia due to impaired renal excretion
B. Reduced effectiveness of the drug in acidic environments
C. Accumulation of the drug leading to lactic acidosis
D. Increased risk of secondary hyperparathyroidism
Answer: C
Conceptual Explanation: Metformin is primarily excreted unchanged by the kidneys. In
severe renal impairment, it can accumulate, significantly increasing the risk of lactic
acidosis, a rare but life-threatening metabolic complication.
2. When prescribing a Cytochrome P450 3A4 (CYP3A4) inducer like Rifampin to a patient
taking Warfarin, what clinical adjustment should the practitioner anticipate?
A. Decrease the Warfarin dose to prevent toxicity
,B. Discontinue Warfarin and switch to a Direct Oral Anticoagulant (DOAC)
C. Increase the Warfarin dose to maintain therapeutic INR
D. No adjustment is needed as Rifampin affects the 2C9 isoenzyme only
Answer: C
Conceptual Explanation: Rifampin is a potent inducer of hepatic enzymes, including those
that metabolize Warfarin. Induction leads to faster metabolism and decreased serum levels
of Warfarin, necessitating a higher dose to maintain the therapeutic International
Normalized Ratio (INR).
3. A patient is diagnosed with Heart Failure with Reduced Ejection Fraction (HFrEF). Which
medication class has been shown to reduce both morbidity and mortality by inhibiting the
effects of the sympathetic nervous system on the myocardium?
A. Loop Diuretics
B. Beta-Adrenergic Blockers
C. Calcium Channel Blockers
D. Cardiac Glycosides
Answer: B
Conceptual Explanation: Beta-blockers (specifically Carvedilol, Metoprolol Succinate, and
Bisoprolol) are essential in HFrEF management because they counteract the deleterious
, effects of chronic sympathetic nervous system activation, improving survival and cardiac
function.
4. In the context of pharmacokinetics, what does the term ‘Volume of Distribution’ (Vd)
primarily represent?
A. The total volume of blood in the human body
B. The theoretical volume required to contain the total amount of drug at the same
concentration as in the plasma
C. The rate at which a drug is cleared from the systemic circulation by the liver
D. The ratio of the dose administered to the total body weight
Answer: B
Conceptual Explanation: Vd is a theoretical value that relates the amount of drug in the
body to the concentration measured in the plasma. A high Vd suggests the drug is
extensively distributed into tissues, while a low Vd suggests it remains mostly in the
vascular space.
5. Which of the following describes the mechanism of action of Angiotensin II Receptor
Blockers (ARBs) that distinguishes them from ACE Inhibitors?
A. They block the conversion of Angiotensin I to Angiotensin II
B. They directly inhibit the release of Renin from the juxtaglomerular cells
C. They increase the levels of Bradykinin, leading to vasodilation
